Pfizer quarterly revenue falls 0.4% to $16.58 billion
Pfizer has slipped into decline. Results for the quarter ended September 27, 2026, from the earnings release filed with the SEC on Nov 3, 2026.
Snapshot
Pfizer has slipped into decline: revenue fell 0.4% to $16.58 billion in the quarter ended September 27, 2026, from $16.65 billion a year earlier, after 2.6% year over year growth the quarter before.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($PFE) | ▼ −2.18% | 30.00 |
as of 16:00 ET · Realtime derived data
What We Know
Revenue for the quarter ended September 27, 2026 was $16.58 billion, versus $16.65 billion in the same quarter a year earlier, down 0.4%.
Quarterly revenue by fiscal quarter end, oldest first: Dec 2024: $17.76 billion; Mar 2025: $13.72 billion; Jun 2025: $14.65 billion; Sep 2025: $16.65 billion; Dec 2025: $17.56 billion; Mar 2026: $14.45 billion; Jun 2026: $15.03 billion; Sep 2026: $16.58 billion.
Octans View
Year over year revenue change by quarter, computed from the filed figures: Dec 2025 down 1.2%; Mar 2026 up 5.4%; Jun 2026 up 2.6%; Sep 2026 down 0.4%. On those figures, Pfizer has slipped into decline. That read compares the latest two year over year growth rates and nothing else.
Bear Case · Room for Disagreement
This brief covers reported revenue and diluted earnings per share only. It does not cover guidance, margins, segment results, cash flow or the earnings call, and it makes no forecast. Revenue is the total on the release line we matched; a company's own adjusted measures can differ.
Method and source. Octans Research matched the revenue line in the earnings release (Exhibit 99.1) to the year ago quarter the company reported in its own XBRL financial data; the two must agree before anything is published. The quarterly history comes from the same XBRL data. The text is generated from those verified figures by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — Pfizer earnings release for the quarter ended September 27, 2026 (Exhibit 99.1), filed Nov 3, 2026
- [2]SEC EDGAR — Pfizer XBRL financial data (company facts)
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
$16.58B
More on $PFE
4 reports
China's Pipeline Goes Global: The Licensing Wave Rewriting Big Pharma's Deal Math
Chinese biotechs signed licensing deals worth more than 60 billion dollars in the first quarter of 2026 alone. The wave is repricing how multinational pharma sources its pipeline, and the deal structures are telling a more nuanced story than the headline numbers.
Pharmaceutical sector weakness points to systemic rotation over pipeline failures
A synchronized 5 day decline across major drugmakers suggests macro factors are overriding individual clinical narratives.
Block quarterly revenue rises 9.9% to $6.72 billion
Block's revenue growth is holding steady. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 3, 2026.
Amgen quarterly revenue rises 8.5% to $10.37 billion
Amgen's revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 3, 2026.